Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

<p>Relative change in target lesion size across cobolimab dose ranges in parts 1c and 1e (<i>N</i> = 27; <b>A</b>) and part 2A (<i>N</i> = 39; <b>B</b>). Note: <i>N</i> number is defined as the safety population minus one patient from...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	Diwakar Davar (15023480) (author)
Altres autors:	Zeynep Eroglu (19276519) (author), Casilda Llácer Pérez (22053013) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Niranjan Yanamandra (22053022) (author), Srimoyee Ghosh (22053025) (author), Kathrin Jansen (22053028) (author), Arindam Dhar (15016280) (author), Theo Borgovan (22053031) (author), Angela Waszak (22053034) (author), Antoni Ribas (14837278) (author)
Publicat:	2025
Matèries:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Immunotherapy Antibody immunotherapy Checkpoint blockade Oncogenes & Tumor Suppressors PD-1 Skin Cancers Melanoma
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!